Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Current Pharmaceutical Design|November 15, 2011
Lipid lowering drugs and gallstones: a therapeutic option?Eirini Lioudaki, Emmanuel S Ganotakis, Dimitri P Mikhailidis
Current Pharmaceutical Design|November 15, 2011
Liver enzymes: potential cardiovascular risk markers?Eirini Lioudaki, Emmanuel S Ganotakis, Dimitri P Mikhailidis
Current Vascular Pharmacology|November 4, 2010
Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 yearsEirini Lioudaki, Emmanuel S Ganotakis, Dimitri P Mikhailidis
Current Pharmaceutical Design|January 3, 2013
Microalbuminuria: a neglected cardiovascular risk factor in non-diabetic individuals?Eirini Lioudaki, Matilda Florentin, Emmanuel S Ganotakis, et al.
Current Pharmaceutical Design|December 7, 2010
The estrogenic burden on vascular risk in male-to-female transsexualsEirini Lioudaki, Emmanuel S Ganotakis, Dimitri P Mikhailidis, et al.
Current Medical Research and Opinion|August 9, 2005
The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitionsVasilios G Athyros, Emmanuel S Ganotakis, Moses Elisaf, et al.
The Open Cardiovascular Medicine Journal|July 3, 2009
Kidney function and estimated vascular risk in patients with primary dyslipidemiaKonstantinos Tziomalos, Emmanuel S Ganotakis, Irene F Gazi, et al.
Journal of the Science of Food and Agriculture|June 12, 2013
The hypolipidaemic effects of Spirulina (Arthrospira platensis) supplementation in a Cretan population: a prospective studyElias E Mazokopakis, Ioannis K Starakis, Maria G Papadomanolaki, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|April 25, 2008
Acute rhabdomyolysis caused by Spirulina (Arthrospira platensis)Elias E Mazokopakis, Christos M Karefilakis, Athanasios N Tsartsalis, et al.
Pageof 4